Vytalyou, a doctor-led startup focused on longevity and preventive healthcare, has secured Rs 9 crore in pre-Series A funding from Chetan Jain of Pharma Dose and Ratan Jain of Venus Industries. The investment values the Mumbai-based company at approximately Rs 33 crore.
The newly raised capital will primarily support the expansion of Vytalyou’s Incremental Lifestyle Clinics across Mumbai, according to a company press release.
Established in 2025 by Chirantan Bose and Preetesh Bhandari, Vytalyou is building a preventive healthcare model centred on longevity. Its approach brings together diagnostic testing, personalised health interventions and medical supervision to help individuals assess and manage potential health risks.
The startup has built a broad range of services covering pathology and radiology, cardio-respiratory assessments, body composition analysis, genetic and cancer screening, gut microbiome testing, personalised IV therapies and regenerative treatments. It also provides non-invasive technologies aimed at managing chronic musculoskeletal pain.
At the centre of its offering is the Predictive Longevity Evaluation, an AI-driven assessment that analyses a person’s overall health profile, biological age and potential risks. Following the assessment, doctors evaluate the findings and formulate a personalised care programme under medical supervision.
Since opening its first centre, Vytalyou claims to have treated nearly 1,000 clients. Walk-in customers account for roughly half of this base, with the remaining clients coming primarily through word-of-mouth recommendations. The company is targeting an expansion to 10 centres across India over the next few years.
Vytalyou is entering a preventive healthcare and longevity market that has been attracting increasing investor interest. Other startups operating in the space include Biopeak, Cent, Elevate Now and Decode Age, which have also raised capital.
In January this year, Biopeak secured $2.7 million in follow-on funding. Cent, founded by Practo co-founder Shashank ND, raised approximately $5 million to develop its AI-powered early-detection platform, which focuses on identifying risks associated with cancer, cardiac, neurological and metabolic conditions.
Elevate Now has raised Rs 18 crore through a seed round, while Decode Age secured Rs 14.48 crore in pre-Series A funding. Decode Age plans to use its capital to further develop its work in longevity research, biomarker discovery, multi-omics and microbiome capabilities.
